Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

Pressure BioSciences, Inc. (OTCQB: PBIO)

Discussion in 'Penny Stocks' started by Giants1967, Jan 9, 2020.

  1. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
  2. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
    PBIO Pressure BioSciences' Revolutionary UST Platform Featured in Leading North American Cannabis Magazine https://www.otcmarkets.com/stock/PBIO/news/story?e&id=1513494
    Cannabis Brightline Article Highlights Potential of PBI's UST Platform to Play Significant Role in Multiple Billion Dollar Markets - Including CBD, Cosmetics, Nutraceuticals, Biopharmaceuticals, and Food/Beverage

    South Easton, Massachusetts--(Newsfile Corp. - January 17, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company's new and innovative Ultra Shear Technology™ ("UST™") platform was featured in Cannabis Brightline, one of North America's leading cannabis publications. The article was written and published by Focus Media Group (FMG) of Halifax, NS, Canada.

    Jason Ellis, President of Vegas CBD Factory, is a recognized expert in the manufacture of cannabinoid-based products. Vegas CBD Factory is located in a 70,000 sq. ft. cGMP and FDA-compliant, state-of-the-art facility in Las Vegas, NV. Mr. Ellis said: "This article highlights a critical issue facing the cannabis market today: the low bioavailability of CBD from CBD-infused products. Because oils (including CBD oil) are not well-absorbed by the water-based systems of humans and other animals, most CBD delivered by ingestion is unfortunately flushed from the body, with very little being absorbed to provide its expected beneficial effects."

    Mr. Ellis continued: "The article by Cannabis Brightline is very timely, as my colleagues in the cannabis market are now beginning to realize that top quality CBD products will only be generated from using high quality, water-soluble nanoemulsions of CBD oil. I have observed first-hand how existing so-called nanoemulsions of CBD oil flatly fail to deliver effective water-solubility or absorption. Conversely, nanoemulsions created by processing CBD oil through PBI's UST platform provided astonishingly immediate and visually apparent water solubility, which years of science tells us will lead to greatly increased bioavailability. We are now considering the purchase of multiple PBI BaroShear K45 UST nanoemulsion systems in 2020."

    The Cannabis Brightline article also discussed two other patented and broadly enabling technology platforms developed, owned, and marketed by PBI. In addition, it included a short summary of the important work being supported by PBI's novel pressure-based instruments in such areas as cancer, heart disease, stroke, infectious diseases, and Alzheimer's Disease. The article is available online and can be accessed by clicking on the following link: The Solution for Maximizing the Bioavailability of CBD and Beyond.

    Richard T. Schumacher, President and CEO of PBI, commented: "It has been very exciting to experience the rapidly growing increase in interest in our UST-based BaroShear K45 nanoemulsification system since the first of the year. In just the past week, we have received nearly a dozen unsolicited phone calls/emails from individuals in North America and Europe. Many callers were aware that our initial build of 12 BaroShear K45 instruments is expected to begin in early 2020, and they wanted to ensure they could secure a spot on the initial build purchase list."

    Mr. Schumacher continued: "Because of strong and growing interest, we remain comfortable with our earlier guidance that BaroShear K45 revenue in 2020 will greatly exceed current revenue from our PCT and BaroFold platforms combined. We look forward with anticipation to the initial release of the BaroShear K45 nanoemulsification system, currently planned for September 2020."
     
  3. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
  4. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
    PBIO
    Introduction of New Benchtop, R&D Scale, UST-Based "BaroShear Mini" in Q3 2020 Expected to Speed Market Penetration of PBI's UST Platform for Processing CBD and Other Oils into Stable, High Quality, Water-Soluble Nanoemulsions
    New Instrument for Product Formulation and Development to Address Many Large and Diverse Markets https://www.otcmarkets.com/stock/PB...le-CBD-with-Planned-Release-of-Addi?id=252638
     
  5. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that Zacks Small Cap Research ("Zacks SCR") has released an updated research report in its on-going coverage on the Company.

    Copies of the new Zacks SCR report can be obtained via the following link:

    https://s1.q4cdn.com/460208960/files/News/2020/Zacks_SCR_Research_02052020_PBIO_Senko.pdf

    Any opinions, judgments, estimates, or forecasts regarding the Company's historical or predicted performance or operations made by Zacks SCR are theirs alone and do not represent opinions, judgments, estimates, or forecasts of the Company or its management. The Company does not by its reference to the research prepared by Zacks SCR imply its endorsement or adoption of or concurrence with such information, conclusions, or recommendations.
     
  6. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
  7. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
  8. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
  9. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
  10. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
  11. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
  12. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
  13. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6
  14. Giants1967

    Giants1967 Member

    Joined:
    Dec 2, 2019
    Messages:
    783
    Likes Received:
    6

Share This Page